Revance Therapeutics, Inc. Form SC 13G February 13, 2017

# **UNITED STATES**

# SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

**SCHEDULE 13G** 

#### Under the Securities Exchange Act of 1934

(Amendment No.)\*

#### **Revance Therapeutics, Inc.**

(Name of Issuer)

**Common Stock, par value \$0.001 per share** (Title of Class of Securities)

**761330109** (CUSIP Number)

December 31, 2016 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

x Rule 13d-1(b)

o Rule 13d-1(c)

o Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSI	P No. <b>761330109</b>	SCH	IEDULE 13G	Page 2 of 6 Pages	
	NAME OF REPO	ORTING PERSC	DNS		
1	Arrowpoint Asset Management, LLC				
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A C (a) o (b) o				
3	SEC USE ONLY				
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware, United States				
	NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON H	5	SOLE VOTING POWER		
l			2,018,729		
Bl		6	SHARED VOTING POWER		
			0		
WITH		_	SOLE DISPOSITIVE POWER		
		7	2,018,729		
		8	SHARED DISPOSITIVE POWE	ER	
			0		
9 AGGRI	EGATE AMOUN	F BENEFICIAL	LY OWNED BY EACH REPORTING F	PERSON	
<b>a</b> 010 <b>a</b>	••				

2,018,729

10

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

o 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

7.1%12TYPE OF REPORTING PERSON

CUSIP No. 761330109	SCHEDULE 13G	Page 3 of 6 Pages				
Item 1. (a) Name of Issuer						
Revance Therapeutics, Inc.						
	(b) Address of Issuer's	Principal Executive Offices				
7555 Gateway Boulevard						
Newark, California 94560						
Item 2.	(a) N	ame of Person Filing				
Arrowpoint Asset Management, LLC						
(b) Address of Principal Business Office, or, if none, Residence						
100 Fillmore Street, Suite 325						
Denver, Colorado 80206						
		(c) Citizenship				
Please refer to Item 4 on each cover sheet for each filing person						
	(d) Title o	of Class of Securities				
Common Stock, par value \$0.001 per share						
		(e) CUSIP No.:				

761330109

CUSIP No. 761330109

**SCHEDULE 13G** 

Page 4 of 6 Pages

# Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a) "Broker or dealer registered under section 15 of the Act (15 U.S.C. 780);
- (b) " Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c) " Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d) <sup>"</sup> Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
- (f) An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
- (g) A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
- (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);

CUSIP No. 761330109

**SCHEDULE 13G** 

Page 5 of 6 Pages

# Item 4. Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

- (a) Amount beneficially owned: 2,018,729
- (b) Percent of class: 7.1%
- (c) Number of shares as to which the person has:
- (i) Sole power to vote or to direct the vote: 2,018,729
- (ii) Shared power to vote or to direct the vote: 0
- (iii) Sole power to dispose or to direct the disposition of: 2,018,729
- (iv) Shared power to dispose or to direct the disposition of: 0

#### Item 5. Ownership of Five Percent or Less of a Class

Not Applicable

#### Item 6. Ownership of More Than Five Percent on Behalf of Another Person

Not Applicable

Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

# Item 8. Identification and Classification of Members of the Group

Not Applicable

#### Item 9. Notice of Dissolution of Group

Not Applicable

# Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. CUSIP No. 761330109

**SCHEDULE 13G** 

Page 6 of 6 Pages

# **SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 13, 2017

Arrowpoint Asset Management, LLC

By: Richard Grove Name: Richard Grove Title: Chief Compliance Officer